JP2023515582A5 - - Google Patents
Info
- Publication number
- JP2023515582A5 JP2023515582A5 JP2022551297A JP2022551297A JP2023515582A5 JP 2023515582 A5 JP2023515582 A5 JP 2023515582A5 JP 2022551297 A JP2022551297 A JP 2022551297A JP 2022551297 A JP2022551297 A JP 2022551297A JP 2023515582 A5 JP2023515582 A5 JP 2023515582A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- poxvirus
- sars
- cov
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981997P | 2020-02-26 | 2020-02-26 | |
| US62/981,997 | 2020-02-26 | ||
| US202063114514P | 2020-11-16 | 2020-11-16 | |
| US63/114,514 | 2020-11-16 | ||
| PCT/US2021/020119 WO2021174142A1 (en) | 2020-02-26 | 2021-02-26 | Recombinant poxvirus based vaccine against sars-cov-2 virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515582A JP2023515582A (ja) | 2023-04-13 |
| JP2023515582A5 true JP2023515582A5 (https=) | 2024-03-04 |
Family
ID=75267580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551297A Withdrawn JP2023515582A (ja) | 2020-02-26 | 2021-02-26 | ＳＡＲＳ－ＣｏＶ－２ウイルスに対する、組換えポックスウイルスに基づくワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210260182A1 (https=) |
| EP (1) | EP4110386A1 (https=) |
| JP (1) | JP2023515582A (https=) |
| KR (1) | KR20220165731A (https=) |
| CN (1) | CN116348135A (https=) |
| AU (1) | AU2021226592A1 (https=) |
| BR (1) | BR112022016992A2 (https=) |
| CA (1) | CA3173996A1 (https=) |
| IL (1) | IL295925A (https=) |
| MX (1) | MX2022010588A (https=) |
| TW (1) | TWI902763B (https=) |
| WO (1) | WO2021174142A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103231A4 (en) * | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| EP4153228A4 (en) * | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20230295655A1 (en) * | 2020-07-31 | 2023-09-21 | Tokyo Metropolitan Institute Of Medical Science | Recombinant vaccinia virus |
| TW202334434A (zh) * | 2021-07-21 | 2023-09-01 | 中央研究院 | 對抗嚴重急性呼吸道症候群冠狀病毒2型之基於痘病毒的疫苗及使用該疫苗的方法 |
| CN113621076A (zh) * | 2021-08-31 | 2021-11-09 | 南华大学 | 一种针对新冠病毒变异毒株Delta的融合蛋白、喷鼻式疫苗及其制备方法和应用 |
| US20250064919A1 (en) * | 2022-01-06 | 2025-02-27 | Board Of Regents, The University Of Texas System | A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine |
| WO2023168286A1 (en) * | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| EP4316514A1 (en) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
| GB2624391A (en) * | 2022-11-15 | 2024-05-22 | Univ Cape Town | Recombinant LSDV vectored bovine coronavirus antigen constructs |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004777A (en) * | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| WO2004091524A2 (en) * | 2003-04-14 | 2004-10-28 | Acambis Inc. | Respiratory virus vaccines |
| US8541003B2 (en) * | 2003-06-20 | 2013-09-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| CN1852921A (zh) * | 2003-07-21 | 2006-10-25 | 美国政府卫生及公众服务部国家卫生协会 | Sars冠状病毒刺突糖蛋白的可溶性片段 |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2005081716A2 (en) * | 2003-11-24 | 2005-09-09 | The Johns Hopkins University | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) |
| WO2005103259A1 (en) * | 2004-04-26 | 2005-11-03 | University Health Network | Sars-cov nucleocapsid protein epitopes and uses thereof |
| EP1778283A2 (en) * | 2004-06-30 | 2007-05-02 | ID Biomedical Corporation of Quebec | Vaccine compositions for treating coronavirus infection |
| JPWO2006022215A1 (ja) * | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| JP4665122B2 (ja) * | 2004-10-08 | 2011-04-06 | 財団法人 東京都医学研究機構 | 組み換えウイルスおよびその用途 |
| CN101020055B (zh) * | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| WO2017047089A1 (en) * | 2015-09-16 | 2017-03-23 | Shin Nippon Biomedical Laboratories, Ltd. | Vaccine compositions |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2021
- 2021-02-26 KR KR1020227033014A patent/KR20220165731A/ko active Pending
- 2021-02-26 CA CA3173996A patent/CA3173996A1/en active Pending
- 2021-02-26 US US17/187,678 patent/US20210260182A1/en active Pending
- 2021-02-26 BR BR112022016992A patent/BR112022016992A2/pt unknown
- 2021-02-26 EP EP21715007.7A patent/EP4110386A1/en active Pending
- 2021-02-26 TW TW110107179A patent/TWI902763B/zh active
- 2021-02-26 JP JP2022551297A patent/JP2023515582A/ja not_active Withdrawn
- 2021-02-26 AU AU2021226592A patent/AU2021226592A1/en active Pending
- 2021-02-26 MX MX2022010588A patent/MX2022010588A/es unknown
- 2021-02-26 IL IL295925A patent/IL295925A/en unknown
- 2021-02-26 CN CN202180027983.6A patent/CN116348135A/zh active Pending
- 2021-02-26 WO PCT/US2021/020119 patent/WO2021174142A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515582A5 (https=) | ||
| JP6818797B2 (ja) | 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答 | |
| Yakubitskiy et al. | Attenuation of vaccinia virus | |
| US20200325477A1 (en) | Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors | |
| EP3329016B1 (en) | Promoters for enhancing expression in poxviruses | |
| CN1842602A (zh) | 修饰的安卡拉牛痘病毒(mva)突变体及其用途 | |
| CA2676809C (en) | Immediate protection against pathogens via mva | |
| JP2021522789A5 (https=) | ||
| Wang et al. | Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain | |
| Joshi et al. | Poxvirus vectors | |
| CA2929600C (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| HK40072005A (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| EA052954B1 (ru) | Вакцина против вируса эпштейна-барр | |
| EA045254B1 (ru) | Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций | |
| HK40044708A (en) | Pr13.5 promoter for robust t-cell and antibody responses | |
| HK1254405B (en) | Promoters for enhancing expression in poxviruses | |
| HK1226774B (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| HK1226774A1 (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| HK1161677B (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |